Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Orchard Therapeutics Plc ADR
(NQ:
ORTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EST, Jan 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Orchard Therapeutics Plc ADR
< Previous
1
2
3
4
5
Next >
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
May 07, 2024
Eight presentations showcase the broad applicability of HSC gene therapy to address rare neurometabolic diseases and beyond
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
May 03, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
March 20, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics: Q3 Earnings Insights
November 13, 2023
Via
Benzinga
Why Orchard Therapeutics Stock Is Soaring Today
October 05, 2023
A buyout offer is fueling a rise in the company's shares today.
Via
The Motley Fool
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
March 18, 2024
One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
February 05, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
February 02, 2024
Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
January 25, 2024
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
January 24, 2024
Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of...
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD
December 11, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH
November 30, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
November 28, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments
November 13, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023
October 26, 2023
New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of...
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023
October 24, 2023
From
Orchard Therapeutics (Europe) Limited
Via
GlobeNewswire
Sarepta Therapeutics Stock Showing Rising Relative Strength
October 09, 2023
Sarepta Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
ORCHARD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Orchard Therapeutics plc - ORTX
October 06, 2023
From
Kahn Swick & Foti, LLC
Via
Business Wire
Crude Oil Down 2%; ConAgra Brands Earnings Top Views
October 05, 2023
U.S. stocks traded slightly lower toward the end of trading, with the Dow Jones index falling around 40 points on Thursday. The Dow traded down 0.12% to 33,088.44 while the NASDAQ fell 0.23% to...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent...
Via
Benzinga
Dow Tumbles Over 100 Points; Constellation Brands Raises Profit Forecast
October 05, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Thursday. The Dow traded down 0.45% to 32,980.31 while the NASDAQ fell 0.62% to 13,154.24. The...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Highly Rated Biotech Orchard Therapeutics Scores A Takeover, Shares Nearly Double
October 05, 2023
The company is working on stem cell-based gene therapies for severe rare diseases.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
October 05, 2023
Via
Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: SP® Plus Corporation (Nasdaq - SP), Orchard Therapeutics plc (Nasdaq - ORTX), Summit Materials (NYSE - SUM)
October 05, 2023
From
Brodsky & Smith LLC
Via
GlobeNewswire
Lamb Weston, SP Plus And Other Big Stocks Moving Higher On Thursday
October 05, 2023
U.S. stocks traded lower, with the Nasdaq Composite falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Dow Falls 50 Points; Weekly Jobless Claims Edge Higher
October 05, 2023
U.S. stocks traded lower this morning, following the release of economic reports. Following the market opening Thursday, the Dow traded down 0.15% to 33,078.88 while the NASDAQ fell 0.28% to 13,199.32....
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Orchard Therapeutics PLC (NASDAQ: ORTX) Sets New 52-Week High in Thursday Session
October 05, 2023
Via
Investor Brand Network
ORTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Orchard Therapeutics plc Is Fair to Shareholders
October 05, 2023
From
Halper Sadeh LLC
Via
Business Wire
Why Is Cambium Networks (CMBM) Stock Down 35% Today?
October 05, 2023
Cambium Networks isn't doing so hot on Thursday with shares of CMBM stock falling alongside preliminary earnings results for Q3!
Via
InvestorPlace
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.